Local Control and survival
The median follow-up for all investigated patients was 85 months (range
47.9-124.2). A total of 23 failures were observed. Recurrence in the
primary tumor site occurred in 10 patients. In addition, 2 patients had
recurrence in the pelvic lymph nodes, 13 patients had distant metastases
alone.
For all investigated patients, the local recurrence free survival rate
at 5 years was 87.6%, metastasis recurrence-free survival at 5 years
was 82.4%, respectively. The estimated overall
actuarial
cancer specific survival rate at 5 years was 76.3%, respectively.
Moreover, 5 years disease free survival rate was 70.9%, respectively.
Analysis of survival according to FIGO stage is shown in Figure 2 and
table S1-4.